Register to receive a free European Market Report Suite for Anesthesia, Respiratory and Sleep Management report synopsis and brochure

ResMed recently announced new European research from Price Waterhouse Coopers (PwC), revealing that patients with sleep apnea who use ResMed’s myAir have greater adherence to CPAP (continuous positive airway pressure) therapy than those who don’t.

myAir is ResMed’s digital and online support program that enables patients to track their own treatment and get personalized coaching tips to support motivation.

The data, published today in a white paper, demonstrate that myAir patients use their device an average 46 minutes longer per night compared to other patients. Furthermore, the average adherence to CPAP treatment for new patients in their first week of treatment is 76% for myAir patients compared to 71% for other patients.

David Jones, Sleep Manager at University Hospital of South Manchester, United Kingdom, commented: “We know that around half of patients are not compliant with their CPAP treatment; this is a major concern for sleep treatment professionals. The effects of poor treatment adherence are profound, not only because of the impact on patients’ quality of life, but also in terms of an increased number of accidents and emergency visits, hospitalizations and the resulting financial burden that this places on healthcare systems. These latest findings confirm that enabling patients to track and improve their CPAP device usage is an important step towards long-term compliance and better patient outcomes.”

PwC’s study, “Empowering the Sleep Apnoea Patient,” analyzed anonymous daily-usage data from over 23,000 patients in Germany and the United Kingdom on CPAP or automatic positive airway pressure (APAP) therapy for sleep apnea. The patients were treated by sleep clinics and home care providers in these two countries, and were all monitored via telemonitoring by their nurse or physician. Over 1,800 of these patients were also registered in myAir.

In addition to receiving data, PwC interviewed several clinics and home care providers in the United Kingdom, Germany and Finland to further investigate the positive influence of myAir on patients and clinics. Usage data and anecdotal evidence were then analyzed for those patients who had and hadn’t registered for myAir.

Christian Käfling from PwC commented: “In recent years, the introduction of telemonitoring has given sleep clinics and home care providers a tool to proactively intervene to help patients starting CPAP treatment. With myAir, telemonitoring has been taken to the next level, and this research has now confirmed that patients who use it show significantly and measurably better adherence and usage than other patients.”

Laurent Morin, ResMed’s EMEA Senior Medical Affairs Director, commented: “The myAir online support program was developed based on principles of behavioral therapy. It has been well documented that patient engagement is key to successful treatment and that involving patients in their treatment improves adherence. myAir’s regular reminders, tailored coaching and positive reinforcement offer a valuable additional level of support to the care already provided by sleep clinics.”

PwC’s study findings in Europe are supported by recent research presented in the United States at CHEST 2016, the annual meeting of the American College of Chest Physicians. The data showed that patients who use a digital self-monitoring tool when treating their sleep apnea with positive airway pressure (PAP) are significantly more likely to continue using their therapy. The observational study of more than 128,000 U.S. patients, the largest-ever study of sleep apnea and digital connected care, showed that more than 87% of PAP users were compliant on therapy when using ResMed’s myAir and AirView™, a clinical remote monitoring tool, compared to 70% compliance for those using AirView alone.

Obstructive sleep apnea is a major public health problem across Europe, and as with other illnesses, poor adherence to treatment is a significant issue for patients and the healthcare professionals who treat them. Sleep apnea involves the recurrent partial or complete collapse of the upper airway during sleep and is usually associated with snoring, oxygen desaturation and sleep fragmentation. CPAP devices prevent collapse of the upper airway by maintaining continuous positive air pressure throughout inspiration and expiration via a mask during sleep.

Laurent Morin commented: “While this study focused on CPAP users, we believe these results may be applied more broadly in terms of the role that online tools can have in improving medical treatment compliance overall.”

For Further Information
More on the anesthesia monitoring market in Europe can be found in a series of reports published by iData Research entitled the European Market Report Suite for Anesthesia, Respiratory and Sleep Management. The suite covers reports on the following markets: Anesthesia Delivery Units, Anesthesia Disposables, Ventilators, Nebulizers, Respiratory Disposables, Oxygen Therapy, Sleep Apnea Devices and Interfaces, and Sleep Diagnostic Devices.

The iData report series on anesthesia, respiratory and sleep management covers the U.S. and 15 countries in Europe including Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about anesthesia, respiratory and sleep management market data or procedure data, register online or email us at [email protected] for a European Market Report Suite for Anesthesia, Respiratory and Sleep Management brochure and synopsis.

About iData Research
iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Dental Operatory Equipment, X-Ray Imaging, Vascular Access, Peripheral Vascular, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Diagnostic Imaging, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Oncology, Ultrasound, Laparoscopy, Urology, Gynecology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large and Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics and more.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.


Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook: facebook.com/iDataResearch
Follow us on LinkedIn: linkedin.com/company/idata-research
Follow us on Twitter: twitter.com/iDataResearch